# Clinical trials of a drug by phase and status: osimertinib

> One query, osimertinib, returns phase counts for 188 registered ClinicalTrials.gov studies and a status table, with EGFR drug context, as of 2026-11-06.

Data as of 2026-11-06 · Published 2026-11-06 · Updated 2026-11-06 · https://bioq.bio/blog/en/howto-clinical-trials-of-a-drug-at-a-glance

![BioQ result page for the query osimertinib showing a ClinicalTrials.gov trial table with phase, status, sponsor, start date and enrollment columns.](https://bioq.bio/blog/img/howto-clinical-trials-of-a-drug-at-a-glance/en/hero.webp)

The query `osimertinib` returns clinical trials of a drug by phase and status in one view: 188 registered studies on ClinicalTrials.gov, of which 57 are phase 1, 105 are phase 2 and 31 are phase 3. The data are as of 2026-11-06. The engine needed 0.61 seconds in total, across 2 engine queries.

## What we asked: clinical trials of a drug by phase and status

The task is common. You have a drug name and want to know how much clinical work is registered for it, how far along that work is, and which studies are still open. For osimertinib, an EGFR inhibitor, this is the usual first step before reading any individual protocol. It helps with a literature background, a competitive scan, or deciding which phase 3 EGFR studies deserve a closer look.

The manual route means opening ClinicalTrials.gov, filtering by intervention, and tallying phases and statuses. If you also want to know where the drug sits among other EGFR drugs, you then open a second resource, such as Open Targets or ChEMBL, and match names by hand. Each step is reasonable, but every one is a separate session with its own filters.

In BioQ the same task is one query: `osimertinib`. It draws on 2 distinct resources and reports its own source for each block.

## What BioQ returned

The first block is the registry view. BioQ matched 188 studies for the intervention osimertinib and counted 57 in phase 1, 105 in phase 2 and 31 in phase 3. The table below is only a page of 8 of those studies, not the full list. The phase counts cover all matched studies.

| Trial | Phase | Status | Sponsor | Start | Enrollment |
|---|---|---|---|---|---|
| NCT04486833 | PHASE1/PHASE2 | RECRUITING | Genprex, Inc. | 2021-09 | 158 |
| NCT04870190 | PHASE3 | UNKNOWN | Shanghai Chest Hospital | 2021-06 | 232 |
| NCT02856893 | PHASE2 | COMPLETED | European Organisation for Research and T | 2017-10 | 156 |
| NCT06417814 | PHASE3 | ACTIVE_NOT_RECRUITING | AstraZeneca | 2024-10 | 768 |
| NCT06304441 | NA | RECRUITING | Guangzhou Medical University | 2024-04 | 100 |
| NCT05153408 | PHASE1 | TERMINATED | Blueprint Medicines Corporation | 2022-01 | 20 |
| NCT04575415 | — | UNKNOWN | Guangdong Association of Clinical Trials | 2020-10 | 272 |
| NCT06303167 | PHASE2 | ACTIVE_NOT_RECRUITING | National Cancer Institute (NCI) | 2016-01 | 19 |

The second block places osimertinib among the drugs known for EGFR. BioQ lists 118 drugs for the gene and shows 6 here. The "Trials by name" column for osimertinib reads 188, which matches the study count in the registry block.

| Drug | Max clinical stage | Mechanism | Best exact pChEMBL | Type | Trials by name |
|---|---|---|---|---|---|
| Osimertinib | APPROVAL | Epidermal growth factor receptor erbB1 inhibitor | 11.7 | IC50 | 188 |
| Afatinib | APPROVAL | Epidermal growth factor receptor erbB1 inhibitor | 11 | IC50 | 112 |
| Mobocertinib | APPROVAL | Epidermal growth factor receptor erbB1 inhibitor | 11 | IC50 | 4 |
| Neratinib | APPROVAL | Epidermal growth factor receptor erbB1 inhibitor | 10.7 | IC50 | 69 |
| Erlotinib | APPROVAL | Epidermal growth factor receptor erbB1 inhibitor | 10.54 | IC50 | 355 |
| Lapatinib | APPROVAL | Epidermal growth factor receptor erbB1 inhibitor | 10.22 | IC50 | 144 |

The engine total for both blocks was 0.61 seconds. That is the measured engine time only. It does not include the time you spend reading the output.

## What it means and how to read it

**Read the phase counts first.** Of 188 studies, 105 are phase 2 and 31 are phase 3. Do not add the three phase counts and expect the study total. Studies labelled with a combined phase, such as the PHASE1/PHASE2 entry in the table, are a plausible reason the figures do not sum to the total. Check how your question treats combined labels before you quote a figure.

**Then read the status column.** In this page of 8, two studies are recruiting, two are active but not recruiting, two have status unknown, one is completed and one is terminated. Because the page is not a random sample, it says nothing about the distribution across all 188 studies. Use it to see what the fields look like and to pick records to open.

**Pick records for the next step.** Two rows in this page are phase 3. NCT06417814 is sponsored by AstraZeneca, is active but not recruiting, started in 2024-10 and lists an enrollment of 768. NCT04870190 is sponsored by Shanghai Chest Hospital, has status unknown, started in 2021-06 and lists an enrollment of 232. Status "unknown" is a registry label, not a statement about whether the study is running. If you need a current status, check the record directly.

**Note the odd rows.** NCT06304441 has phase "NA" and NCT04575415 has no phase shown ("—"). Both are listed among the osimertinib studies, but this table cannot tell you why they have no phase. Open the registry record before counting them in any phase analysis.

**Use the drug table for context.** Osimertinib, afatinib, mobocertinib, neratinib, erlotinib and lapatinib all show a maximum clinical stage of APPROVAL with an EGFR (erbB1) inhibitor mechanism. The best exact pChEMBL for osimertinib is 11.7 (IC50), against 11.0 for afatinib and 10.54 for erlotinib. pChEMBL is the negative log10 of the molar potency, so a higher value means a more potent measurement. These values come from different assays, so treat the comparison as a pointer to the underlying ChEMBL records. By name, erlotinib has 355 registered trials, so a trial count mostly reflects how long and how widely a drug has been studied.

**What to do next.** For phase 3 EGFR work in NSCLC, open the phase 3 records that interest you and check the conditions, eligibility and arms there. The table above does not show indication, and BioQ does not infer it here.

## How to reproduce it in BioQ

1. Open BioQ and go to the search box.
2. Paste the query below exactly as written.

```text
osimertinib
```

[Open this query in BioQ](https://bioq.bio/login?next=%2Fapp%23q%3Dosimertinib)

3. Wait for the result blocks. You should see the registry block with the study count and phase counts, and the EGFR drug block with the stage table.
4. Read the phase counts for the whole set, then use the table page to pick records. Every block names its source and release.
5. Note the data date shown with the answer. Registry data change, so a later run can return different counts than the 2026-11-06 figures here.

To explore a different drug, replace the name in the query. To ask about another gene's drugs, state the gene and the question in plain words.

## Limits: what the data do not show

- The table is a page of 8 studies out of 188. It is not sorted by phase and not representative of the full set.
- Phase counts depend on how the registry labels phases. Combined phases and missing phases ("NA" or no value) make simple tallies ambiguous.
- Status is as registered. "Unknown" means the registry has no recent confirmation, not that a study has stopped.
- The registry block does not show conditions, outcomes or results. It cannot tell you which studies are in NSCLC, nor whether any study met its endpoint.
- Matching is by intervention name. Studies that use osimertinib in combination are matched by the same name, and the data here do not separate monotherapy from combinations.
- The pChEMBL values come from different assays and do not rank clinical value. Nothing here is medical, dosing or treatment advice.

## Data and method
The numbers on this page were read from the BioQ engine on 2026-11-06 (2 queries, 0.6 s of engine time in total). The tables are generated by code from the engine's answers; the text only restates them.

`/clinicaltrials`, `/drugs`

Run the same query yourself: [osimertinib](https://bioq.bio/login?next=%2Fapp%23q%3Dosimertinib)

*For research use only. This page summarises public data and is not medical advice.*

BioQ is an AI search engine and agent with one goal: making biology research 100X faster. Ask in the web app, over the REST API, or from Claude, ChatGPT or Cursor through MCP.

## Queries used

- [`osimertinib`](https://bioq.bio/login?next=%2Fapp%23q%3Dosimertinib)

## Frequently asked questions

### How many osimertinib trials are registered on ClinicalTrials.gov?

BioQ matched 188 studies for osimertinib as of 2026-11-06. Of these, 57 are phase 1, 105 are phase 2 and 31 are phase 3.

### How many phase 3 osimertinib trials are there?

The registry block counts 31 phase 3 studies among the 188 matched. Two of the 8 studies shown on the first page are phase 3: NCT06417814 and NCT04870190.

### Why don't the phase counts add up to the total number of studies?

The phase counts (57, 105 and 31) are not meant to be added to reach 188. Combined-phase labels such as PHASE1/PHASE2 and studies with no phase are plausible reasons for the mismatch, so check the registry record for any study you count.

### How long does the osimertinib query take?

The measured engine time was 0.61 seconds across 2 engine queries. That figure covers the engine only, not the time you spend reading the results.

### Does this query tell me which osimertinib trials are in NSCLC?

No. The table shows phase, status, sponsor, start and enrollment, but not condition. Open the individual registry record to check the condition and eligibility.

## Sources

- Dataset: [ClinicalTrials.gov](https://clinicaltrials.gov/)
- Dataset: [Open Targets Platform; ChEMBL; Drug Repurposing Hub](https://platform.opentargets.org/)

> Results come from public databases as of the date shown and may change. BioQ gives research information, not medical advice.
